申请人:ZERIA PHARMACEUTICAL CO., LTD.
公开号:EP0997457A1
公开(公告)日:2000-05-03
The present invention is directed to 3-benzoylindole derivatives represented by the following formula (I):
(wherein R1 represents a lower alkyl group, n is an integer from 1 to 5; each of R2 and R3 represents a hydrogen atom, a lower alkyl group, or an optionally substituted phenyl group; and R4 represents a hydrogen atom, a lower alkyl group, or a benzyl group) and to a pharmaceutical containing the same. This compound is endowed with strong α1-adrenergic receptor blocking action and strong testosterone 5α-reductase inhibitory action, as well as high level of safety, and thus is useful as an excellent preventive or therapeutic drug for prostatic hypertrophy or accompanying urination disorder, alopecia, and acne.
本发明涉及下式(I)代表的3-苯甲酰基吲哚衍生物:
(其中 R1 代表低级烷基,n 为 1 至 5 的整数;R2 和 R3 分别代表氢原子、低级烷基或任选取代的苯基;R4 代表氢原子、低级烷基或苄基)以及含有这些衍生物的药物。该化合物具有很强的α1-肾上腺素能受体阻断作用和很强的睾酮-5α-还原酶抑制作用,而且安全性很高,因此可作为前列腺肥大或伴随的排尿障碍、脱发和痤疮的一种很好的预防或治疗药物。